Halozyme Reports Third Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Halozyme Therapeutics (HALO) Misses Q3 EPS by 5c
November 12, 2019 4:32 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.17), $0.05 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $46.2 million versus the consensus estimate of $54.93 million.
GUIDANCE:
Halozyme Therapeutics sees FY2019 revenue of $195-205 million, versus the consensus of $204.9... More
